Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

AstraZeneca64 enrolled

Overview

To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Adverse Events Pharmacokinetic

Interventions

ABT-143DRUG

once daily for 6 days

ABT-335DRUG

once daily for six days

RosuvastatinDRUG

Once daily for 6 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * General good health * BMI 19 to 29 Exclusion Criteria: * Currently enrolled in another study * Females who are pregnant or breastfeeding

Locations (1)

Site Reference ID/Investigator# 8089

Orlando, Florida, United States

Outcomes

Primary Outcomes

Adverse event and safety laboratory assessments

Time frame: 7 days

Pharmacokinetic parameters

Time frame: 7 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.